Eleusis SPAC

Key Investment Highlights 1 2 3 eleusis Significant Market Opportunity 2nd Generation Psilocybin Drug Candidate for MDD A First-in-Class Care Delivery Management Company ■ ■ ■ Antidepressant total addressable market (TAM) expected to reach $21bn by 2025¹ US psychedelic care delivery TAM estimated to be ~$7bn² ELE-Psilo is our lead product candidate, comprised of the active ingredient in psilocybin formulated for IV delivery Targeting a consistent, controllable, and practical psilocybin-based therapy for the treatment of MDD Anticipated initiation of Phase I studies in 1H 2022 Anticipated Phase I results in healthy volunteers and MDD patients in 2H 2022 Andala is an operationally integrated platform of "in-network" clinics targeting the "last mile" challenge of psychedelic drug therapy Anticipated Cash Flow Positive Clinic Operations in 1H 2023 Source: 1) Global Antidepressants Market Report 2021: COVID-19 Causes a Surge in Demand for Antidepressant Drugs as Mental Health Problems Rise - ResearchAnd Markets.com, Business Wire, April 26, 2021; 2) Partheniou, A. (2021) Psychedelics - A possible disrupter to legacy treatments, Stifel Nicholaus Canada Inc., January 14, 2021 (estimate based in part on data from existing ketamine clinics). 5

View entire presentation